Jame Abraham,Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic, shared a post on X:

“Bispecific Antibody Glotiftamab Combination with Chemoimmunotherapy Safe and Effective for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy.”

More posts featuring Jame Abraham.

Jame Abraham, MD, FACP, is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and a Professor of Medicine at Cleveland Clinic Lerner College of Medicine. He also is a Deputy Editor at the ASCO Post and Journal of Oncology Practice of ASCO.

Dr. Abraham is a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee and holds leadership roles in NRG Oncology and the National Surgical Adjuvant Breast and Bowel Project (NSABP).

Jame Abraham: Glotiftamab combination shows safety and efficacy for relapsed large B-cell lymphoma